Reviews/Dietary Fibre/Fibre lowers colorectal cancer risk
Gastrointestinal · FIBRE-GI-01 · v2
Borderline: within 4 points of the Likely/Uncertain boundary, so a re-grade could land either side.
The corpus asks whether eating more fibre lowers the chance of developing colorectal cancer. The one study that tests cause directly in humans, using inherited genetic variation as a natural experiment, finds that higher fibre intake is protective [24], and this fits a human study where people with pre-cancerous growths ate less fibre [1] and animal studies where fibre reduced tumours [2],[11]. But no study here follows people long enough to count actual cancers; the trials instead measure early warning markers, and the two most direct of those found no benefit [5],[18]. One animal study even found that a processed form of fibre made tumours worse in an inflamed gut [12]. The panel therefore treated the claim as supported in direction but not firmly proven, because the strongest human proof of actual cancer prevention is missing from this corpus.
The only direct causal human test, a Mendelian-randomization analysis, reports that higher fibre intake protects against colorectal cancer (OR 0.249, 95% CI 0.083-0.744) [24]. This is consistent with a case-control study linking lower fibre intake to advanced colorectal adenoma [1] and with animal azoxymethane models where fibre or resistant-starch synbiotics reduced neoplasms and aberrant crypt foci [2],[11]. However, the most direct human intervention trials on surrogate endpoints were null: a phase II trial found no convincing evidence of risk reduction from prebiotic inulin [5], and a dietary-intervention analysis did not modify bile-acid concentrations [18]. No study in the corpus uses colorectal cancer incidence or mortality as an endpoint, and [12] reports refined inulin promoting inflammation-associated tumorigenesis in mice. The contested point: The division is between the single causal and associational human signals that point to protection ([24],[1]) and the interventional evidence, which is either null on its surrogate endpoints ([5],[18]) or actively counter-directional for a refined fibre ([12]). The corpus never closes the chain from fibre to a counted cancer, so the direction is supported but the interventional backbone is weak and partly conflicting.
All 24 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Dietary Fibre, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
No corpus paper uses CRC incidence or mortality as an endpoint. Every human trial ([3],[5],[7],[14],[18]) measures surrogates (aberrant crypt foci, adenoma recurrence, DNA adducts, WNT markers), so the causal chain from fibre to actual cancer is never closed in a trial.
The two most direct human interventions are null: [5] states 'do not provide convincing evidence of CRC risk reduction', and [18]'s dietary intervention 'did not modify BA concentrations'. The strongest interventional data in the corpus do not support the claim.
Where it remains uncertain. The two most direct human intervention trials were null on surrogate endpoints [5],[18], and refined inulin promoted tumorigenesis in one model [12], so fibre type and the absence of a hard-endpoint trial qualify the claim.
Aleatory
The sole causal estimate [24] spans OR 0.083-0.744, a broad range that only just excludes no effect.
Epistemic
The corpus contains no study using colorectal cancer incidence or mortality as an endpoint, so the fibre-to-cancer chain is never closed experimentally.
Inferential
Protective signals in rat AOM models [2],[11] must be assumed to transfer to human colorectal cancer risk, not demonstrated.
The load-bearing papers from a corpus of 24, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Human associational support at the adenoma (CRC precursor) level.
“A high-fiber dietary pattern and subsequent consistent production of SCFAs and healthy gut microbiota are associated with a reduced risk of A-CRA.”
Panel auditInternal validity: low · scope of inference: Association between habitual fiber intake and presence of advanced colorectal adenoma in a Chinese clinical sample.Key limitations: adenoma not cancer · observational · no risk estimate reported
Animal mechanistic support (resistant starch), indirect to human claim.
“Rats fed RS in combination with B.lactis showed significantly lowered incidence and multiplicity of colonic neoplasms (P < 0.01) by >50% compared with the control group.”
Panel auditInternal validity: medium · scope of inference: Effect of resistant starch, with or without B. lactis, on azoxymethane-induced colonic neoplasms in rats.Key limitations: animal model · RS alone not significant · significant effect was synbiotic not fibre alone
Null direct human interventional evidence on the ACF surrogate; tempers the claim.
“Data from this multicenter, phase II trial do not provide convincing evidence of CRC risk reduction from 6-month interventions with atorvastatin, sulindac, or ORAFTI®Synergy1, although statistical power was limited by the relatively small sample size.”
Panel auditInternal validity: medium · scope of inference: Effect of 6-month inulin supplementation on rectal aberrant crypt foci in people with prior colon cancer or advanced adenomas.Key limitations: underpowered · surrogate endpoint · short 6-month duration
Adding the fibre prevented the red-meat-induced rise in a carcinogenesis-related adduct, consistent with a protective mechanism.
Panel auditInternal validity: medium · scope of inference: Effect of butyrylated starch on rectal O6MeG adduct formation in healthy adults eating red meat.Key limitations: surrogate biomarker not cancer · n=23 · specific engineered fibre
4 of 24 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Direct causal and associational human evidence carries a supportive verdict, but null surrogate trials, a counter-signal, and the absence of any hard-endpoint trial hold it to the low end of Likely.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No cancer-endpoint trial. Nothing in the corpus tests fibre against counted colorectal cancer incidence or mortality, so the causal chain stops at surrogates. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A long-duration randomised trial of increased dietary fibre with colorectal cancer incidence as the primary endpoint.
Open question: Does increasing dietary fibre intake reduce colorectal cancer incidence or mortality, not just surrogate markers? Why it is still open: No study in the corpus uses a cancer incidence or mortality endpoint; all human trials measure surrogates ([3],[5],[7],[14],[18]).
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19